Haemonetics Stock Price, News & Analysis (NYSE:HAE)

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Haemonetics announced that its Board of Directors has initiated a share buyback program on Tuesday, February 6th 2018, which permits the company to buyback $260,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to repurchase shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company's board believes its stock is undervalued.

Haemonetics Co. (NYSE:HAE) announced its earnings results on Tuesday, August, 6th. The medical instruments supplier reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.18. The medical instruments supplier had revenue of $238.50 million for the quarter, compared to the consensus estimate of $236.82 million. Haemonetics had a net margin of 5.05% and a return on equity of 21.07%. The firm's revenue for the quarter was up 4.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.59 EPS. View Haemonetics' Earnings History.

Haemonetics is scheduled to release their next quarterly earnings announcement on Friday, November 1st 2019. View Earnings Estimates for Haemonetics.

Haemonetics will be holding an earnings conference call on Friday, November 1st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Haemonetics issued an update on its FY20 earnings guidance on Tuesday, August, 6th. The company provided earnings per share (EPS) guidance of $2.95-3.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.94. The company issued revenue guidance of +3-5% yr/yr to ~$996.6 million to $1.02 billion, compared to the consensus revenue estimate of $1.00 billion.

5 brokerages have issued 12 month price objectives for Haemonetics' stock. Their predictions range from $139.00 to $150.00. On average, they anticipate Haemonetics' share price to reach $144.40 in the next twelve months. This suggests a possible upside of 12.9% from the stock's current price. View Analyst Price Targets for Haemonetics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Haemonetics.

Press coverage about HAE stock has trended neutral this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Haemonetics earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave media stories about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Haemonetics.

Haemonetics saw a decline in short interest in September. As of September 30th, there was short interest totalling 826,400 shares, a decline of 13.5% from the August 30th total of 955,900 shares. Based on an average trading volume of 353,700 shares, the days-to-cover ratio is presently 2.3 days. Currently, 1.6% of the shares of the company are short sold. View Haemonetics' Current Options Chain.

Some companies that are related to Haemonetics include ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Insulet (PODD), ABIOMED (ABMD), Novocure (NVCR), Hill-Rom (HRC), Integra Lifesciences (IART), Penumbra (PEN), Globus Medical (GMED), Tandem Diabetes Care (TNDM), NuVasive (NUVA), ICU Medical (ICUI), Cantel Medical (CMD) and Nevro (NVRO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include Endologix (ELGX), Align Technology (ALGN), Apache (APA), Chipotle Mexican Grill (CMG), Zoetis (ZTS), Micron Technology (MU), Adobe (ADBE), NVIDIA (NVDA), Aegean Marine Petroleum Network (ANW) and CA (CA).

Haemonetics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Pacer Advisors Inc. (0.04%), Envestnet Asset Management Inc. (0.02%), State of Alaska Department of Revenue (0.02%), Crossmark Global Holdings Inc. (0.01%), Meeder Asset Management Inc. (0.01%) and Campbell & CO Investment Adviser LLC (0.01%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Mark W Kroll, Michelle L Basil, Neil Mr Ryding, Pedro P Granadillo, Richard J Meelia, Ronald G Gelbman, Said Bolorforosh, Susan Bartlett Foote, Willaim P Burke and William P Mr Burke. View Institutional Ownership Trends for Haemonetics.

HAE stock was sold by a variety of institutional investors in the last quarter, including Baldwin Brothers Inc. MA, Pacer Advisors Inc., First Citizens Bank & Trust Co. and Crossmark Global Holdings Inc.. Company insiders that have sold Haemonetics company stock in the last year include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Michelle L Basil, Neil Mr Ryding, Pedro P Granadillo, Richard J Meelia, Ronald G Gelbman, Said Bolorforosh and William P Mr Burke. View Insider Buying and Selling for Haemonetics.

HAE stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Envestnet Asset Management Inc., Meeder Asset Management Inc., Campbell & CO Investment Adviser LLC and Nisa Investment Advisors LLC. View Insider Buying and Selling for Haemonetics.

Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of HAE stock can currently be purchased for approximately $127.91.

Haemonetics has a market capitalization of $6.49 billion and generates $967.58 million in revenue each year. The medical instruments supplier earns $55.02 million in net income (profit) each year or $2.39 on an earnings per share basis. Haemonetics employs 3,216 workers across the globe.View Additional Information About Haemonetics.

The official website for Haemonetics is http://www.haemonetics.com/.

Haemonetics' mailing address is 400 WOOD RD, BRAINTREE MA, 02184. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]